Publications
The Lancet · Human Vaccines & Immunotherapeutics

Published Evidence

The vaccine trials we conducted were published in international peer-reviewed journals, led by The Lancet, one of the most influential medical journals in the world. The citations below include full reference details together with study design, scale, and key findings.

L
Publication 1 — The Lancet · 2021

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Tanrıöver MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, ve ark.; CoronaVac Çalışma Grubu. Lancet. 2021;398(10296):213-222.

DOI
10.1016/S0140-6736(21)01429-X
PMID
34246358
PMCID
PMC8266301
NCT
NCT04582344
Key Findings
  • ✓10,218 participants at 24 centers; vaccine efficacy 83.5% (95% CI 65.4-92.1)
  • ✓No fatal or grade 4 adverse events observed
  • ✓Funded by TÜSEB; coordinated by Hacettepe University
PubMed ↗ PMC (Full Text) ↗ Trial Page →
Publication 2 — Hum Vaccin Immunother · 2022

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial

Omma A, Batirel A, Aydin M, Yılmaz Karadağ F, Erden A, ve ark. — Hybrid COV-RAPEL TR Çalışması.

DOI
10.1080/21645515.2022.2122503
PMID
36315843
NCT
NCT04979949
Key Findings
  • ✓Wuhan variant positivity: TURKOVAC 46.2% → 100%; CoronaVac 52.6% → 98.2%
  • ✓Markedly higher response against the Delta variant in the TURKOVAC arm (8.7% → 80.6%)
  • ✓Both booster doses yielded high antibody titers with acceptable safety profiles
PubMed ↗ PMC (Full Text) ↗ Trial Page →
Publication 3 — Hum Vaccin Immunother · 2024

The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac inactivated COVID-19 vaccines

Durusu Tanrıöver M, Altuntaş Aydın O, Güner R, Yıldız O, Çelik İ, Köse Ş, ve ark.; TURKOVAC Çalışma Grubu.

DOI
10.1080/21645515.2024.2346388
PMID
38924774
Key Findings
  • ✓The impact of prior COVID-19 history on adverse events was evaluated in 1,266 participants
  • ✓Local adverse events 37.3%, systemic 39.0%; no severe events
  • ✓TURKOVAC and CoronaVac showed similar adverse event profiles within the first 30 minutes
PubMed ↗ PMC (Full Text) ↗ Trial Page →
Why It Matters

Peer-Reviewed Publication Is Proof of Quality

Publication of a clinical trial in an international peer-reviewed journal means that the methodology, data quality, and ethical compliance have been independently reviewed and approved by experts. Being published in a journal like The Lancet means passing through some of the strictest editorial and peer-review processes in the world.

These publications document the auditability of the operations we conduct, the reliability of our data, and the permanence of the scientific contribution. They serve as a reference point for future vaccine and biologic trials.

Your trial deserves publication too

Benefit from our end-to-end clinical research services, including medical writing and publication support.

Contact Us